Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors

NCT00815945 is registered in ClinicalTrials.gov with AGO Study Group as lead sponsor.

NCT NCT00815945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00815945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study Evaluating PegLiposomal Doxorubicin (PLD) and Carboplatin Combination Chemotherapy in Gynecological Sarcomas and Mixed Epithelial-Mesenchymal Tumors
Lead sponsor
AGO Study Group
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2008
Completion date
January 31, 2012
Enrollment
41 (actual)
Sites
15

Conditions

As the registry lists them; a condition with its own page is linked.

carcinosarcoma, leiomyosarcoma, mesenchymal tumor